• 1
    Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol 2006; 50:130615.
  • 2
    Coyne KS, Sexton CC, Vats V, et al. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology 2011; 77:10817.
  • 3
    Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87:7606.
  • 4
    Benner JS, Becker R, Fanning K, et al. Bother related to bladder control and health care seeking behavior in adults in the United States. J Urol 2009; 181:25918.
  • 5
    Brown JS, Vittinghoff E, Wyman JF, et al. Urinary incontinence: Does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc 2000; 48:7215.
  • 6
    DuBeau CE, Levy B, Mangione CM, et al. The impact of urge urinary incontinence on quality of life: Importance of patients' perspective and explanatory style. J Am Geriatr Soc 1998; 46:68392.
  • 7
    Nuotio M, Tammela TL, Luukkaala T, et al. Predictors of institutionalization in an older population during a 13-year period: The effect of urge incontinence. J Gerontol A Biol Sci Med Sci 2003; 58:75662.
  • 8
    Nuotio M, Tammela TL, Luukkaala T, et al. Urgency and urge incontinence in an older population: Ten-year changes and their association with mortality. Aging Clin Exp Res 2002; 14:4129.
  • 9
    Kraus SR, Bavendam T, Brake T, et al. Vulnerable elderly patients and overactive bladder syndrome. Drugs Aging 2010; 27:697713.
  • 10
    Sand PK, Heesakkers J, Kraus SR, et al. Long-term safety, tolerability and efficacy of fesoterodine in subjects with overactive bladder symptoms stratified by age: Pooled analysis of two open-label extension studies. Drugs Aging 2012; 29:11931.
  • 11
    Wagg A, Khullar V, Marschall-Kehrel D, et al. Flexible-dose fesoterodine in elderly subjects with overactive bladder: Results of the randomized, double-blind, placebo-controlled SOFIA trial. J Am Geriatr Soc 2013; doi: 10.1111/jgs.12088. [Epub ahead of print].
  • 12
    Coyne KS, Margolis MK, Hsieh R, et al. Validation of the urinary sensation scale (USS). Neurourol Urodyn 2011; 30:3605.
  • 13
    Colman S, Chapple C, Nitti V, et al. Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder. Urology 2008; 72:8037.
  • 14
    Coyne KS, Matza LS, Kopp Z, et al. The validation of the patient perception of bladder condition (PPBC): A single-item global measure for patients with overactive bladder. Eur Urol 2006; 49:107986.
  • 15
    Cardozo L, Coyne KS, Versi E. Validation of the urgency perception scale. BJU Int 2005; 95:5916.
  • 16
    Piault E, Evans CJ, Espindle D, et al. Development and validation of the overactive bladder satisfaction (OAB-S) questionnaire. Neurourol Urodyn 2008; 27:17990.
  • 17
    Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: The OAB-q. Qual Life Res 2002; 11:56374.
  • 18
    Kraus SR, Ruiz-Cerdá JL, Martire D, et al. Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder. Urology 2010; 76:13507.
  • 19
    Dubeau CE, Morrow JD, Kraus SR, et al. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder. Neurourol Urodyn 2012; 31:125865.
  • 20
    DuBeau C, Kraus SR, Griebling TL, et al. Fesoterodine is effective and well tolerated in vulnerable elderly subjects with urgency incontinence: A double-blind, placebo-controlled study. J Urol 2012; 187:e5489.
  • 21
    Martín-Merino E, García-Rodríguez LA, Masso-Gonzalez EJ, et al. Do oral antimuscarinic drugs carry an increased risk of acute urinary retention? J Urol 2009; 182:14428.
  • 22
    Herschorn S, Jones JS, Oelke M, et al. Efficacy and tolerability of fesoterodine in men with overactive bladder: A pooled analysis of 2 Phase III studies. Urology 2010; 75:114955.
  • 23
    Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007; 52:120412.
  • 24
    Nitti VW, Dmochowski R, Sand PK, et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol 2007; 178:248894.
  • 25
    Wagg A, Compion G, Fahey A, et al. Persistence with prescribed antimuscarinic therapy for overactive bladder: A UK experience. BJU Int 2012; 110:176774.